Project Grant K99HL173553
- This R03 project grant, awarded by the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350, aims to comprehensively identify metabolic enzymes that control the generation of TCF1+ progenitor CD8+ T cells, which are critical for durable anti-tumor immune responses. The $169,500 award, spanning from September 1, 2024 to August 31, 2026, will fund two key research objectives: Identifying metabolic enzymes whose loss alters T cell differentiation and the TCF1+...
- This $423,000 Project Grant was awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the direct regulation of cell cycle genes by cell identity factors during myeloid differentiation. Specifically, the project aims to determine how transcription factors PU.1 and C/EBP regulate the expression of cyclin-dependent kinase inhibitors and cyclin D2 to induce cell cycle...
- This $225,306 Project Grant award from the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports a collaborative research project between researchers at the University of Southern California (USC) and a German partner to investigate the long-term impact of early-life growth signals on adult hematopoietic (blood) stem cell function and selection. The key products and services to be delivered under this 3-year award include: 1) using stem cell transplantation and...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $445,000 to The Children's Hospital of Philadelphia Research Institute under the Cardiovascular Diseases Research program (CFDA 93.837) on July 15, 2025, for a three-year project extending through June 30, 2028. This Project Grant funds research to determine the genetic mechanisms driving hematopoietic stem and progenitor cell (HSPC) production in vitro. The research focuses on the tropomyosin 1 gene's role...
- Federal Grant Award Summary Baylor College of Medicine received a $104,359 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on February 26, 2025, with a completion date of November 30, 2026. The project, titled "Cellular Interactions and Competition in Clonal Hematopoiesis," involves research into how mutations in hematopoietic stem cells—specifically in genes DNMT3A (DNA methyltransferase...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $166,644 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on July 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). This five-year grant extends through June 30, 2030, and supports research investigating inflammatory responses in human hematopoietic stem cells, with particular focus on how aging and clonal hematopoiesis...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $153,117 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year physician-scientist training and research initiative spanning August 1, 2025, through July 31, 2030. The award funds the career development of a hematopathology physician-scientist at the University of Pennsylvania and Children's Hospital of Philadelphia to establish an independent research...
- This Project Grant award of $162,080, made by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), supports research conducted by The Johns Hopkins University from December 27, 2025 through June 30, 2028. The funded research, led by Dr. Komatsu's laboratory, focuses on visualizing B cell infiltration and aggregation within the tumor microenvironment to advance cancer immunotherapy development. The project delivers foundational scientific insights through...
- This Project Grant award of $746,800 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research conducted by Baylor College of Medicine to define the major signaling mechanisms controlling spontaneous cardiomyocyte (CM) proliferation during the neonatal stage. The research objectives include identifying and characterizing the CD36 transmembrane scavenger receptor pathway's role in regulating CM proliferation in...
MOLECULAR REGULATION OF LYMPHOID LINEAGE PRIMING IN STEADY STATE AND REGENERATION - PROJECT SUMMARY/ABSTRACT: CONTINUOUS FUNCTIONAL T AND B LYMPHOID OUTPUT IS CRITICAL TO OVERALL HEALTH AND LIFE, AS DELAYED AND REDUCED LYMPHOPOIETIC OUTPUT HAS BEEN ASSOCIATED WITH SERIOUS ILLNESS AND EVEN MORTALITY. THE LYMPHOID SYSTEM IS PARTICULARLY SENSITIVE TO HEMATOPOIETIC PERTURBATION, BOTH IN THE CONTEXT OF STEADY STATE AND REGENERATION. HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) INTO IRRADIATED RECIPIENTS AND STRESS FROM INFECTION OR OTHER INSULTS IN NATIVE HEMATOPOIETIC SYSTEMS HAVE BEEN SHOWN TO NEGATIVELY REGULATE LYMPHOID OUTPUT. ONE OF THE CHALLENGES TO DEVELOPING CLINICAL THERAPIES TO RESTORE HEALTHY IMMUNE FUNCTION IS THAT WE DON'T HAVE ENOUGH INFORMATION ON LYMPHOID DEVELOPMENT IN VIVO. THIS IS TRUE FOR BOTH THE EMBRYONIC IMMUNE SYSTEM WHICH HPSC BLOOD DIFFERENTIATION SYSTEMS ATTEMPT TO REPRODUCE AND THE ADULT IMMUNE SYSTEM. UNDERSTANDING THE MECHANISMS BY WHICH LYMPHOID OUTPUT FROM HSPCS IS CONTROLLED AT CLONAL, TRANSCRIPTIONAL, AND EPIGENETIC LEVELS IS CRITICAL FOR REVEALING HOW LYMPHOID OUTPUT IS ESTABLISHED AND REGULATED IN STEADY STATE, HOW IT IS SUPPRESSED WITH REGENERATION, AND WHETHER THERE IS A SPECIFIC SIGNATURE ASSOCIATED WITH REDUCED LYMPHOID OUTPUT THAT IS CONSERVED BETWEEN NATIVE AND NON-NATIVE SYSTEMS. IT WAS RECENTLY SHOWN THAT THE HSC SPECIFIC TRANSCRIPTION FACTOR TCF15 IS INDISPENSABLE FOR LONG TERM SELF-RENEWAL, FOLLOWING HSCT. INTRIGUINGLY, I HAVE DEMONSTRATED THAT TCF15 ALSO NEGATIVELY REGULATES BOTH T AND B LYMPHOID DIFFERENTIATION. THIS WAS TRUE BOTH IN NATIVE HEMATOPOIESIS AND REGENERATION. IT IS WELL ESTABLISHED THAT HSCS DISPLAY MULTILINEAGE PRIMING. THIS ALLOWS HSCS TO READILY REGENERATE THE HEMATOPOIETIC SYSTEM, UPON PERTURBATION AND TO DIFFERENTIATE INTO LINEAGE RESTRICTED PROGENITOR CELLS TO MEET NATIVE HEMATOPOIETIC DEMANDS. IN ADDITION, REDUCED LYMPHOID LINEAGE PRIMING HAS BEEN SHOWN TO PROMOTE HSC EXPANSION. FOR THE MENTORED K99 PHASE OF THIS PROPOSAL, I WILL TRANSITION FROM A FOCUS ON TCF15 IN NATIVE HEMATOPOIESIS, TO A FOCUS ON TCF15 IN LYMPHOPOIESIS, A FOCUS THAT WILL ALLOW ME TO ESTABLISH RESEARCH INDEPENDENCE FROM MY MENTOR. WITH THE EVIDENCE OF MULTILINEAGE HSC PRIMING, THE EVIDENCE OF NATIVE ANTAGONISM BETWEEN HSC SELF-RENEWAL AND LYMPHOID DIFFERENTIATION PROGRAMS, AND MY PRELIMINARY DATA HYPOTHESIZE THAT TCF15 EXPRESSION ATTENUATES LYMPHOID LINEAGE PRIMING IN HSCS AND THAT THIS IS CONSERVED BETWEEN STEADY STATE AND REGENERATION. I PROPOSE TO TEST THIS HYPOTHESIS IN TWO AIMS: IN AIM 1, I WILL APPLY SCRNA- SEQ, SCATAC-SEQ, AND PROTEOMIC ANALYSES TO ELUCIDATE THE TRANSCRIPTIONAL AND EPIGENETIC PROGRAM BY WHICH TCF15 REGULATES T AND B LYMPHOID DIFFERENTIATION FROM HSPCS. IN AIM 2, I WILL USE TCF15 REPORTER AND CRISPR- BASED LINEAGE TRACING (CARLIN) MOUSE MODELS GENERATED IN OUR LAB TO EXPLORE THE EFFECT OF ENDOGENOUS TCF15 ON T AND B CELL SPECIFICATION FROM HSCS. FOR THE R00 COMPONENT OF THIS AWARD, I WILL SEEK TO CONTINUE MY EXAMINATION OF REGULATION OF LYMPHOID LINEAGE PRIMING, BUT DOWNSTREAM OF HSCS, EXPLORING WHETHER I CAN APPLY LINEAGE AND TRANSCRIPTIONAL TRACING METHODS TO RETROACTIVELY CONNECT T AND B CELL DIFFERENTIATION OUTCOMES TO DISTINCT LYMPHO-MYELOID PRIMED PROGENITORS (LMPP) IDENTITIES IN HEALTH AND AGE, IN AN UNBIASED MANNER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 1/18/26 | ||
| Not listed | $0 | 6/16/25 | ||
| Not listed | $0 | 6/16/25 | ||
| Not listed | $148.4k | 7/25/24 | ||
| Not listed | $148.4k | 7/25/24 |